Financings in Brief: Life Medical Sciences
This article was originally published in The Gray Sheet
Life Medical Sciences: Raises $2.5 mil. in the placement of 909,091 shares of unregistered common stock with an "unrelated third party investor." The shares, sold for $2.75 each, will represent about 17% of total outstanding shares in the Princeton, New Jersey-based company. The purchaser of the shares "will have a demand registration right after one year and certain limited piggyback rights," the company notes. The proceeds will be used for working capital, and to expand clinical testing of the company's products, including its Cariel dermal gel, which employ tissue culturing technology for topical wound healing...
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.